Tonix Pharmaceuticals Holding Corp.(TNXP)Earnings, Financials & Key RatiosTonix Pharmaceuticals Holding Corp. (TNXP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's inability to generate positive operating cash flow, evidenced by a -$42.3 million outflow in 2026Q1, suggests that ongoing dilution remains a primary risk for long-term equity holders.
Tonix Pharmaceuticals Holding Corp. (TNXP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Recent stock market news and headlines for Tonix Pharmaceuticals Holding Corp. (TNXP)
HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults with MDD
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Key metrics vs top competitors for Tonix Pharmaceuticals Holding Corp. (TNXP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.71 | $202.61M | -0.87 | 29.85% | -946.22% | -64.48% | — | |
| $242.60 | $12.48B | -65.92 | 65.55% | -26.59% | -260.01% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $91.61 | $9.83B | 111.72 | 12.79% | 6.23% | 7.5% | — | |
| $25.59 | $1.01B | 159.94 | 3.63% | 1.27% | 1.31% | — |
Tonix Pharmaceuticals Holding Corp. (TNXP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Tonix Pharmaceuticals Holding Corp. (TNXP) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 15, 2026·SEC
May 11, 2026·SEC
May 7, 2026·SEC
Mar 12, 2026·SEC
Get notified when TNXP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tonix Pharmaceuticals Holding Corp. (TNXP) stock FAQ — growth, dividends, profitability & financials explained
Tonix Pharmaceuticals Holding Corp. (TNXP) reported $17.6M in revenue for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. (TNXP) grew revenue by 29.8% over the past year. This is strong growth.
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a net loss of $147.4M for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. (TNXP) has a return on equity (ROE) of -64.5%. Negative ROE indicates the company is unprofitable.
Tonix Pharmaceuticals Holding Corp. (TNXP) had negative free cash flow of $132.7M in fiscal year 2025, likely due to heavy capital investments.
